Regenxbio (RGNX) has experienced a significant decline of -17.56% on June 5, 20251. This drop may be attributed to recent clinical trial updates.
On June 5, 2025, Regenxbio announced new interim data from its Phase 1/2 AFFINITY DUCHENNE trial for RGX-202, a gene therapy for Duchenne muscular dystrophy. Despite the positive results showing continued benefit to patients and a favorable safety profile, the market reacted negatively. This could be due to higher-than-expected doses being used in the trial, which may have raised concerns about potential side effects or the therapy's long-term efficacy23.